Short Interest in OnKure Therapeutics, Inc. (NASDAQ:OKUR) Grows By 211.1%

Posted by Brian Himes on Jul 15th, 2026

OnKure Therapeutics, Inc. (NASDAQ:OKUR – Get Free Report) was the recipient of a large growth in short interest during the month of June. As of June 30th, there was short interest totaling 878,668 shares, a growth of 211.1% from the June 15th total of 282,400 shares. Currently, 2.2% of the company’s stock are short sold. Based on an average daily volume of 755,793 shares, the days-to-cover ratio is currently 1.2 days.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. JonesTrading downgraded OnKure Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 7th. Weiss Ratings upgraded shares of OnKure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 29th. Finally, Wall Street Zen raised shares of OnKure Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $27.00.

View Our Latest Research Report on OKUR

OnKure Therapeutics Trading Up 2.7%

NASDAQ OKUR opened at $4.22 on Wednesday. The company has a 50 day moving average of $4.13 and a 200-day moving average of $3.69. The company has a market cap of $170.49 million, a price-to-earnings ratio of -0.97 and a beta of 0.27. OnKure Therapeutics has a 1-year low of $1.91 and a 1-year high of $5.38.

OnKure Therapeutics (NASDAQ:OKUR – Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.37). On average, equities research analysts forecast that OnKure Therapeutics will post -3.19 earnings per share for the current year.

Institutional Investors Weigh In On OnKure Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of OKUR. XTX Topco Ltd bought a new position in OnKure Therapeutics in the second quarter valued at about $25,000. Jane Street Group LLC bought a new position in OnKure Therapeutics in the 4th quarter valued at approximately $56,000. Hsbc Holdings PLC bought a new position in OnKure Therapeutics in the 4th quarter valued at approximately $58,000. Barclays PLC boosted its position in OnKure Therapeutics by 4,286.8% during the 4th quarter. Barclays PLC now owns 27,242 shares of the company’s stock worth $79,000 after buying an additional 26,621 shares during the period. Finally, Rangeley Capital LLC acquired a new stake in OnKure Therapeutics during the 2nd quarter worth approximately $71,000. Institutional investors own 90.98% of the company’s stock.

About OnKure Therapeutics

(Get Free Report)

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.